Showing Results for: “diabetes”

In Wisconsin, the ADA’s “friend of the court” brief urges changes be made to give those with diabetes and other chronic conditions safer access to vote On Monday, The American Diabetes Association® (ADA) filed an amicus curiae, or “friend of the court” brief in the federal court case Edwards et al. v. Vos et al. in the U.S. District Court for the Western District of Wisconsin, alleging that key changes are needed to enable people with diabetes and other chronic diseases to vote safely in this year’s elections. Proceeding without these changes would violate the U.S. Constitution and the

Long-time Eureka resident Brad Albee began 2020 looking for a way to commemorate his 50th year of thriving with diabetes since his early childhood diagnosis with type 1 diabetes in 1970. It was then that he selected the American Diabetes Association’s (ADA) Wine Country Tour de Cure to celebrate this incredible accomplishment. Brad knew he wanted to celebrate his Silver ‘Diaversary’ (i.e., anniversary of being diagnosed with diabetes) on a bike, specifically on a recumbent bike, which is Brad’s preferred way of getting the outdoors exercise he seeks as a vital component of his regimen to stay

In a victory for children with disabilities, a federal court ruled today that the City of New York’s Department of Education (“DOE”) routinely denies students with diabetes access to field trips and bus transportation in violation of the Americans with Disabilities Act (“ADA”), Section 504 of the Rehabilitation Act (“Section 504”), and the New York City Human Rights Law (“NYCHRL”). Plaintiffs in this lawsuit are the American Diabetes Association ® (“Association”), the nation’s leading diabetes organization, and three individual students with diabetes who attend New York City schools. Click

For people with type 2 diabetes (T2D) and chronic kidney disease (CKD), canagliflozin, an oral, sodium-glucose co-transporter-2 (SGLT2) inhibitor, has a renal- and cardiovascular-protective effect in reducing the progression of kidney impairment, according to the results of the CREDENCE trial presented today in a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. In the first of several renal outcomes studies of SGLT2s, the landmark Canagliflozin and Renal Events in Diabetes with Established Nephropathy

On May 22, 2019, Colorado Governor Jared Polis signed the first bill in the nation that will cap insulin co-pays at $100 per month, regardless of the number of vials needed. House Bill 1216: Reduce Insulin Prices, also enlists the Colorado Attorney General to investigate the rising price of insulin in Colorado and make recommendations to the General Assembly for further action. The American Diabetes Association (ADA) applauds Governor Polis and bill sponsors, Representative Dylan Roberts and Senators Kerry Donovan and Kevin Priola, for their leadership on this important legislation to reduce

Symposium previews new content for Standards of Care in Overweight and Obesity , designed to improve patient care and outcomes Recent developments for the new Standards of Care in Overweight and Obesity guidelines, the first clinical guidance of its kind, were presented during the Standards of Care in Overweight and Obesity 2025 Updates symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago. The Obesity Association™, a division of the ADA, recently announced the publication of Weight Stigma and Bias : Standards of Care in Overweight and Obesity—2025

The American Diabetes Association ® (ADA) welcomes the 2023 Principal Officers and Board of Directors. The 13-member board is comprised of forward-thinking, innovative medical, scientific, education, and executive business professionals, who will strategically lead and focus efforts to ensure the ADA continues to uphold the mission upon which it was founded. "We are so excited to announce our 2023 Board of Directors,” said Charles Henderson, CEO of the ADA. “We look forward to the insight and skills that each of these thought leaders will provide to help move the needle and improve the lives

Sun Life U.S. has renewed its national collaboration with the American Diabetes Association® (ADA), continuing its support of Project Power for youth, a comprehensive national initiative designed to engage, educate and empower young people to embrace healthier lifestyles. The goal of the program is to help reduce the risk of obesity and type 2 diabetes. Support of the ADA and diabetes programming is part of Sun Life's focus on broadening access to health services and programs for communities at higher risk for developing diabetes. Through this two-year renewal, Sun Life will invest $125,000

The American Diabetes Association ® (ADA) applauds TennCare’s decision to provide coverage for Food and Drug Administration (FDA)-approved weight-management medications. TennCare’s coverage of obesity medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, will give more people access to this life-changing treatment option. Approximately 38% of the adult population in Tennessee live with obesity and could benefit from access to this patient-centered treatment. “GLP-1 medications offer the rare opportunity to better manage chronic conditions, improve health, reduce medical

My name is Gibran, and I’ve been living with type 1 diabetes for 27 years. I was in the fourth grade when I was diagnosed at 9 years old. My diabetes journey in the beginning was a rollercoaster with an A1C of 11.1, and managing it felt overwhelming. I would have my endocrinologist, nutritionist, and mom educate me about the long-term complications if I didn’t do better at managing my diabetes. At the end of the day, I was just a kid who loved sweet treats, juice, and playing soccer. My experience with DKA [diabetic ketoacidosis] was one of the toughest moments of my life. I felt nauseous and